Provided by Tiger Trade Technology Pte. Ltd.

MannKind

4.16
+0.09002.21%
Volume:3.19M
Turnover:13.33M
Market Cap:1.34B
PE:-29.71
High:4.24
Open:4.10
Low:4.10
Close:4.07
52wk High:6.51
52wk Low:2.23
Shares:321.54M
Float Shares:309.97M
Volume Ratio:0.82
T/O Rate:1.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1400
EPS(LYR):0.0200
ROE:32.74%
ROA:0.79%
PB:-19.91
PE(LYR):208.00

Loading ...

MannKind announces milestones in development of nintedanib DPI for IPF

TIPRANKS
·
Jun 03

MannKind enrolls first patient in Phase 2 INFLO-2 trial of inhaled nintedanib for IPF

Reuters
·
Jun 03

MannKind Enters Data-Rich Development Period With Completion of Randomization in Phase 1B Inflo-1 Study and Enrollment of First Patient in Phase 2 Inflo-2 Trial for Nintedanib DPI in Patients With Ipf

THOMSON REUTERS
·
Jun 03

MannKind - Expects Phase 1B Inflo-1 Data Readout in Q3 2026

THOMSON REUTERS
·
Jun 03

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 03

MannKind says FDA approves Afrezza for children aged 6 and older with diabetes

Reuters
·
Jun 02

Analysts Offer Insights on Healthcare Companies: MannKind (MNKD) and Option Care Health (OPCH)

TIPRANKS
·
Jun 01

Wells Fargo Sticks to Its Buy Rating for MannKind (MNKD)

TIPRANKS
·
Jun 01

MannKind price target raised to $11 from $10 at Wells Fargo

TIPRANKS
·
Jun 01

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

GlobeNewswire
·
May 30

MannKind Shares Rise 6.4% After US FDA Approves Co's Inhaled Insulin for Children

THOMSON REUTERS
·
May 30

MannKind announces FDA approval of Afrezza for use in children aged 6 and older

TIPRANKS
·
May 30

BRIEF-Mannkind Says Afrezza Available To Eligible Patients For $35 Or Less Per Month

Reuters
·
May 30

MannKind says FDA approves Afrezza inhaled mealtime insulin for children aged 6 and older

Reuters
·
May 30

MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living With Diabetes

THOMSON REUTERS
·
May 30

MannKind - Afrezza Available to Eligible Patients for $35 or Less per Month

THOMSON REUTERS
·
May 30

Analysts Conflicted on These Healthcare Names: MannKind (MNKD), Biohaven Ltd. (BHVN) and Precision BioSciences (DTIL)

TIPRANKS
·
May 28

MannKind Released From Major Afrezza Trial Obligation

TIPRANKS
·
May 28

BRIEF-Mannkind Says FDA Releases Company From Postmarketing Requirement For Afrezza On May 27 - SEC Filing

Reuters
·
May 28

MannKind - FDA Releases MannKind From Postmarketing Requirement for Afrezza on May 27, 2026 - SEC Filing

THOMSON REUTERS
·
May 28